Boehringer Ingelheim releases ambroxol HCl tablets

Published: 2009-12-22 06:56:00

Updated: 2009-12-22 06:56:00

Boehringer Ingelheim Korea said it has launched Mucoangin (ambroxol HCl), a troche-type mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus.

The substance is a mucoactive drug with several properties including secretolytic and secretomotoric...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK